VSIG4

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, February 28, 2024
Active, VSIG4, MSS, National Cancer Institute, Society, Sensei, Lung cancer, Patient, Immunotherapy, Trial of the century, Head, Neoplasm, VISTA, SITC, MBA, Annual general meeting, Therapy, Histology, Biology, NSCLC, ESMO, Kinetics, CRC, PD-1, Conference, Safety, Cemiplimab, Pharmacokinetics, CRADA, CD39, IND, Colorectal cancer, Translation, NCI, Aes, Part-time, FDA, Research and development, Administration, KOL, Cancer, Pharmaceutical industry

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2023, and provided corporate updates.

Key Points: 
  • “2023 saw the entry of our differentiated anti-VISTA antibody, SNS-101, into clinical development,” said John Celebi, President and Chief Executive Officer.
  • Recent updates include:
    A total of 33 patients have been treated with SNS-101 +/- Libtayo in the dose escalation phase of this study.
  • On October 23, 2023 , Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Retrieved on: 
Thursday, January 4, 2024
Biology, Sensei, Lung cancer, CD28, CRC, Neoplasm, Tumor microenvironment, Biotechnology, IND, DLT, FDA, VSIG4, CMO, Research, Colorectal cancer, MSS, Physician, Cancer, Pharmacokinetics, CD39, Head, Novartis, Exelixis, Part-time, Histology, VISTA, American College, Genentech, Internal medicine, Oncology, Patient, Safety, Therapy, NSCLC, Pharmaceutical industry

BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones.

Key Points: 
  • BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones.
  • In the monotherapy dose escalation arm, patients have cleared all planned dosing cohorts of 0.3, 1, 3, 10 and 15 mg/kg.
  • Anticipated milestones for the SNS-101 Phase 1/2 clinical trial include:
    Sensei announces that Ron Weitzman, M.D., F.A.C.P., has joined Sensei as part-time Chief Medical Officer.
  • As a result, Sensei will pause IND-enabling work on its preclinical-stage TMAb programs, including SNS-102 (VSIG4), SNS-103 (CD39) and SNS-201 (VISTAxCD28).

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 7, 2023
VISTA, Research, Insurance, Research and development, The Year's Best Science Fiction: Twenty-Seventh Annual Collection, Northwest Biotherapeutics, ESMO, CD28, Therapy, Society for Immunotherapy of Cancer, VSIG4, Active, Safety, Conference, Translation, MBA, R, Protein, Pharmacokinetics, SITC, Immunotherapy, Sensei, Neoplasm, CD39, Cytokine release syndrome, Annual general meeting, Kinetics, CET, Tumor microenvironment, Society, Cancer, European Society for Medical Oncology, Patient, Administration, MS, Toxicity, Pharmaceutical industry, Vaccine, Cryptocurrency, Antibody, Science, Survival

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2023, and provided recent business updates.

Key Points: 
  • On October 23, 2023, Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.9 million for the quarter ended September 30, 2023, compared to $4.8 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $7.1 million for the quarter ended September 30, 2023, compared to $13.4 million for the quarter ended September 30, 2022.

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, August 3, 2023
Bispecific monoclonal antibody, KOL, Sensei, Therapy, Biochemistry, Neoplasm, Drug discovery, Clinical trial, CRADA, Cancer, Lead, Northwest Biotherapeutics, Research, Antibody, Washington University in St. Louis, Bangladesh Technical Education Board, National Cancer Institute, Patient, Pathology, Administration, CD39, VISTA, VSIG4, Research and development, Immunology, R, FDA, NCI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry, Vaccine, Fine chemical, Cryptocurrency, Development

BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2023, and provided recent business updates.

Key Points: 
  • “The second quarter of 2023 was momentous for Sensei as we moved expeditiously from the FDA’s clearance of our SNS-101 trial in April to the enrollment of six patients by the end of July.
  • Recent updates for SNS-101 include:
    An Investigational New Drug (IND) application for SNS-101 was cleared by the U.S. Food and Drug Administration (FDA) in April 2023.
  • On June 1, 2023, Sensei reported the first patient dosed in the dose escalation portion of the SNS-101 multi-center Phase 1/2 clinical trial.
  • Net Loss: Net loss was $9.4 million for the quarter ended June 30, 2023, compared to $10.5 million for the quarter ended June 30, 2022.

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, May 9, 2023
GLP, Sensei, AACR, Therapy, Food and Drug Administration, CRADA, Cancer, Clinical trial, Pharmacokinetics, American Association for Cancer Research, Northwest Biotherapeutics, Tumor microenvironment, Bangladesh Technical Education Board, Trial of the century, National Cancer Institute, Investigational New Drug, Patient, Administration, CD39, VISTA, VSIG4, Research and development, R, Research, FDA, NCI, Kinetics, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry, Vaccine, Fine chemical, Cryptocurrency

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2023, and provided recent business updates.

Key Points: 
  • Sensei expects to begin clinical trial enrollment and commence patient dosing at a starting dose of 0.3 mg/kg in mid-2023.
  • SNS-103: In April 2023, Sensei presented new preclinical data on SNS-103 at the American Association for Cancer Research (AACR) Annual Meeting.
  • Research and Development (R&D) Expenses: R&D expenses were $5.2 million for the quarter ended March 31, 2023, compared to $7.5 million for the quarter ended March 31, 2022.
  • Net Loss: Net loss was $10.2 million for the quarter ended March 31, 2023, compared to $12.4 million for the quarter ended March 31, 2022.

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, March 28, 2023
Society, AACR, Therapy, Regeneron Pharmaceuticals, CRS, Clinical trial, CRADA, Cancer, SITC, American Association for Cancer Research, Immunotherapy, Research, Neoplasm, Washington University in St. Louis, Antibody, Proteomics, National Cancer Institute, Society for Immunotherapy of Cancer, Investigational New Drug, Cooperative research and development agreement, Cytokine release syndrome, Patient, Administration, CD39, Risk, VISTA, Annual general meeting, VSIG4, Research and development, R, PD-1, NCI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Kinetics, Immunosuppression, Tumor microenvironment, Food, Safety, Pharmaceutical industry, Vaccine, Risk management, Fine chemical, Cryptocurrency, Sensei, Development

BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for full-year 2022 and provided recent business updates.

Key Points: 
  • Recent updates for SNS-101 include:
    In March 2023, Sensei submitted an IND application to the U.S. Food and Drug Administration for the planned Phase 1/2 clinical trial of SNS-101 in patients with solid tumors.
  • SNS-103: Sensei has identified eight parental pH-sensitive CD39 antibodies and begun further optimization on a lead antibody set.
  • In December 2022, Sensei promoted Edward van der Horst, Ph.D., to Chief Scientific Officer.
  • Net Loss: Net loss was $48.6 million for the year ended December 31, 2022, compared to $36.8 million for the year ended December 31, 2021.

Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Private Securities Litigation Reform Act, Concluding observations on the second periodic report of the Holy See, IND, Kinetics, Phrase, VISTA, PCR, Northwest Biotherapeutics, CD4, Tumor microenvironment, FDA, Annual general meeting, Nasdaq, Cytokine release syndrome, LRC, Immunotherapy, Macrophage, Risk, CD8, Proteomics, VSIG4, Society for Immunotherapy of Cancer, Neutrophil, Monocyte, CRS, SEC, Annual report, NASDAQ, Antibody, Immunoglobulin G, Safety, U.S. Securities and Exchange Commission, Gene expression, Blood, SITC, Cancer, CD39, Neoplasm, Multiplexing, Patient, Memory, Therapy, Society, NHP, Vaccine, Sensei

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented preclinical data for SNS-101, a conditionally active VISTA-blocking antibody, as well as characterization of VSIG4, an immune checkpoint targeted by Sensei’s discovery-stage SNS-102 program, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Key Points: 
  • We look forward to advancing both programs with an upcoming IND filing for SNS-101 and identification of a lead anti-VSIG4 antibody in 2023.
  • Summary: Sensei characterized endogenous expression patterns of VSIG4 in polarized macrophage populations and showed a robust VSIG4-mediated suppression of primary human T-cells.
  • Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Review, Investigational New Drug, IND, Northwest Biotherapeutics, Research and development, Tumor microenvironment, Immunosuppression, Annual general meeting, Nasdaq, Cytokine release syndrome, Immunotherapy, Risk, Mouse, Primate, KOL, Society for Immunotherapy of Cancer, ATP, R, Cancer, Translation, PD-1, Survival, Pharmacokinetics, Company, CD39, The Year's Best Science Fiction: Twenty-Sixth Annual Collection, Clinical trial, Tumor-associated macrophage, Poster, Research, Conference, ET, Patient, GMP, Therapy, Administration, Society, NHP, SITC, Vaccine, Pharmaceutical industry, Fine chemical, Cryptocurrency, Science, VSIG4, Sensei

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2022 and provided recent business updates.

Key Points: 
  • Recent updates for SNS-101 include:
    On Friday, November 11, 2022, Sensei will present new preclinical data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, MA.
  • On Monday, November 21, 2022, Sensei will host a virtual KOL webinar Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint.
  • Research and Development (R&D) Expenses: R&D expenses were $9.2 million for the quarter ended September 30, 2022, compared to $6.4 million for the quarter ended September 30, 2021.
  • Net Loss: Net loss was $13.4 million for the quarter ended September 30, 2022, compared to $9.7 million for the quarter ended September 30, 2021.

Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, August 9, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Primate, GLOBE, R, Science, Tumor-associated macrophage, Cancer, Northwest Biotherapeutics, IND, Research, ATP, Research and development, Blood, Patient, Company, Therapy, Tumor microenvironment, GMP, VSIG4, NASDAQ, Translation, Sixth, Survival, Conference, CD39, Food, Administration, VISTA, Investigational New Drug, Vaccine, Pharmaceutical industry, Fine chemical, Lithium

BOSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the second quarter ended June 30, 2022 and provided recent business updates.

Key Points: 
  • - On track with SNS-102 candidate selection, including generation of pH-sensitive parental antibodies -
    BOSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the second quarter ended June 30, 2022 and provided recent business updates.
  • We have also achieved a milestone with the generation of pH-sensitive antibodies for a second program targeting VSIG4.
  • In April 2022, Sensei presented preclinical data demonstrating that SNS-101 had a favorable pharmacokinetic profile in a single-dose mouse model.
  • Net Loss: Net loss was $10.5 million for the quarter ended June 30, 2022, compared to $9.8 million for the quarter ended June 30, 2021.

Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, May 10, 2022
Board, Immune system, Sensei, IND, NASDAQ, GLOBE, VISTA, Safety, Research, Toxicology, Tumor microenvironment, Immunotherapy, ATP, Administration, Cancer, GMP, Blood, Therapy, CD39, Research and development, R, Congress, Northwest Biotherapeutics, G&A, Fish acute toxicity syndrome, Growth, Tumor-associated macrophage, Pharmaceutical industry, Vaccine, Online gambling, Video game, VSIG4

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the first quarter ended March 31, 2022, and provided recent corporate updates.

Key Points: 
  • BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the first quarter ended March 31, 2022, and provided recent corporate updates.
  • Recent updates for SNS-101 include:
    In April 2022 Sensei presented preclinical data demonstrating that SNS-101 had a favorable pharmacokinetic profile in a single-dose mouse model.
  • In January 2022, Sensei announced the promotions of Erin Colgan to Chief Financial Officer and Robert Pierce, M.D., to Chief R&D Officer.
  • Net Loss: Net loss was $12.4 million, for the quarter ended March 31, 2022, compared to $8.0 million for the quarter ended March 31, 2021.